Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 05, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes and Transactions
- December 1, 2006: Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("GSK Trust"), transferred 149,464 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- December 4, 2006: The GSK Trust sold 2,254 Ordinary Shares on behalf of participants in the GlaxoSmithKline Share Value Plan at a price of GBP13.53 per share.
- December 4, 2006: The GSK Trust transferred 8,101 Ordinary Shares to participants in the GlaxoSmithKline Share Value Plan.
Management Commentary and Risks
The GSK Trust is identified as a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Three directors—Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop—are noted as having an interest in the shares held in the GSK Trust in the same capacity as other employees. The filing states that these transactions were notified in accordance with Disclosure Rule 3.1.4R(1)(b). No specific risks, contingencies, or unusual items beyond the standard disclosure of director interests are detailed.
Investor Verification Points
- Verify the total number of shares transferred to employee plans (149,464 + 8,101) and the volume sold (2,254) against internal cap tables.
- Confirm the transaction price of GBP13.53 per share aligns with the market price on December 4, 2006.
- Review the specific holdings of Directors Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop to ensure compliance with insider trading regulations.
- Note that this filing contains no financial performance data; refer to Form 20-F for fiscal results.